Antibiotic resistance is one of the most serious challenges facing hospitals across India today. When a patient in the ICU does not respond to a standard antibiotic, the consequences can be life-threatening. Doctors need a more powerful solution — one that can break through bacterial defences and deliver results fast.
CeftoQub S-750 Injection, manufactured by Cubic Lifesciences Private Limited, is exactly that solution. It combines Ceftriaxone 500 mg and Sulbactam 250 mg in a single sterile vial — creating a dual-action injectable antibiotic designed specifically for complex, resistant bacterial infections in hospital settings.
In this guide, we explain what CeftoQub S-750 is, how it works, what infections it treats, who should use it, and what doctors and franchise partners need to know about it.
What is CeftoQub S-750 Injection?
CeftoQub S-750 is a sterile dry powder injectable formulation containing two active pharmaceutical ingredients:
- Ceftriaxone 500 mg — A third-generation cephalosporin antibiotic with broad-spectrum bactericidal activity against a wide range of Gram-positive and Gram-negative bacteria.
- Sulbactam 250 mg — A beta-lactamase inhibitor that blocks the enzymes produced by resistant bacteria to destroy antibiotics, restoring the full effectiveness of Ceftriaxone.
The 500 mg + 250 mg ratio in CeftoQub S-750 is optimised for targeted use in moderate-to-severe infections. The product is available in a single vial presentation and can be administered both intravenously (IV) and intramuscularly (IM), depending on clinical need.
CeftoQub S-750 is manufactured by Cubic Lifesciences Private Limited in a WHO-GMP and ISO-certified facility at Panchkula, Haryana — the same pharmaceutical hub that produces some of India’s most trusted medicines. The company has been operating since 2013 with a product portfolio of over 700 formulations and 2,000+ active distribution partners across India.
Also available: CeftoQub (Ceftriaxone only, without Sulbactam) — for infections that do not involve resistant strains. CeftoQub S-750 includes Sulbactam for cases where bacterial resistance is suspected or confirmed. Explore the full Cubic Lifesciences injectable range at cubiclifesciences.in/product-category/injectable/
How Does Ceftriaxone + Sulbactam Work in the Body?
Understanding how this combination works helps appreciate why it is preferred in resistant infection scenarios.
Step 1 — Ceftriaxone Attacks the Bacteria
Ceftriaxone is a bactericidal antibiotic. It works by binding to penicillin-binding proteins (PBPs) on the bacterial cell surface. These proteins are responsible for building and maintaining the bacterial cell wall. When Ceftriaxone blocks them, the bacterial cell wall breaks down, and the bacteria die. This action is effective against a wide range of bacteria — but only if the bacteria cannot destroy the antibiotic first.
Step 2 — Sulbactam Protects the Antibiotic
Many bacteria have evolved to produce enzymes called beta-lactamases. These enzymes chemically break down antibiotics like Ceftriaxone before they can do their job. Sulbactam is an irreversible beta-lactamase inhibitor — it binds to these enzymes and permanently deactivates them. With the defensive enzymes neutralised, Ceftriaxone can work without interruption.
The Result — Synergistic Bacterial Kill
Together, Ceftriaxone and Sulbactam achieve what neither could do as well alone — a synergistic antibacterial effect that covers a broader range of pathogens, including those that have developed resistance to standard cephalosporins. This is why this combination is classified as a beta-lactam/beta-lactamase inhibitor (BL/BLI) therapy — one of the most important antibiotic strategies in modern critical care.
What Infections is CeftoQub S-750 Used For?
CeftoQub S-750 is prescribed by doctors and hospital specialists for a wide range of serious bacterial infections. Here is the complete list of indications:
| Indication / Infection Type | Clinical Context |
| Severe Pneumonia / HAP | Hospital-acquired pneumonia and lung abscesses caused by resistant organisms |
| Septicemia (Bloodstream Infection) | Life-threatening bacterial infections in the blood requiring immediate IV therapy |
| Intra-Abdominal Infections | Peritonitis, biliary tract infections, and complicated abdominal sepsis |
| Pelvic Inflammatory Disease (PID) | Severe gynaecological infections of the female reproductive system |
| Bone & Joint Infections | Osteomyelitis and septic arthritis requiring prolonged parenteral therapy |
| Surgical Site Prophylaxis | Pre-operative and post-operative prevention of infection in major surgeries |
| Complicated UTI | Urinary tract infections resistant to standard oral antibiotic therapy |
| Bacterial Meningitis | Infections of the meninges surrounding the brain and spinal cord |
In India, this combination is also widely used in complicated cases of enteric fever (Typhoid) that have not responded to standard oral antibiotics — a common real-world need given rising resistance patterns in India.
Important: CeftoQub S-750 is a prescription-only medicine. It must be administered by or under the supervision of a qualified healthcare professional. It is not for self-medication or use outside a clinical setting.
Why is This Combination Especially Important in India?
India has one of the highest rates of antibiotic resistance in the world. The widespread misuse of antibiotics — incomplete courses, wrong dosages, over-the-counter availability — has led to a significant rise in multidrug-resistant (MDR) organisms in hospitals across the country.
Pathogens like Extended-Spectrum Beta-Lactamase (ESBL) producing E. coli and Klebsiella pneumoniae — which are among the most common causes of hospital-acquired infections in India — are often resistant to plain Ceftriaxone. However, they remain sensitive to Ceftriaxone when it is protected by Sulbactam.
This makes the Ceftriaxone + Sulbactam combination a clinically critical tool in Indian ICUs, surgical wards, and gynaecology departments — where resistant infections are most commonly encountered.
A multicentre clinical study showed an average cure rate of 77.1% for Ceftriaxone + Sulbactam in lower respiratory tract infections in India — validating its real-world effectiveness in Indian patients and Indian infection patterns.
Key Clinical Benefits of CeftoQub S-750 for Healthcare Professionals
- Broad-Spectrum Coverage: Effective against both Gram-positive and Gram-negative pathogens, including ESBL-producing strains commonly encountered in Indian hospitals.
- Rapid Systemic Action: As an injectable, CeftoQub S-750 achieves therapeutic blood levels within minutes of administration — essential in time-critical sepsis and ICU scenarios.
- Long Half-Life of Ceftriaxone: Allows once or twice daily dosing, simplifying administration in ICU and ward settings and reducing nursing burden.
- Excellent Tissue Penetration: Reaches difficult-to-treat anatomical sites, including the pleural cavity, peritoneum, pelvic organs, bone tissue, and CSF (cerebrospinal fluid in meningitis).
- Dry Powder Formulation: The sterile powder form ensures maximum stability and full potency at the time of reconstitution and administration.
- WHO-GMP Certified Manufacturing: Manufactured by Cubic Lifesciences in a WHO-GMP and ISO-certified facility — ensuring consistent purity, safety, and quality across every batch.
Dosage and Administration: What Doctors Need to Know
The standard adult dose of Ceftriaxone + Sulbactam is 1.5 g to 3 g administered every six to twelve hours, depending on the severity of the infection and clinical judgement.
For CeftoQub S-750 (500 mg Ceftriaxone + 250 mg Sulbactam), the dosing frequency and route (IV or IM) will be determined by the treating physician based on:
- The type and severity of the infection
- The patient’s age, weight, and kidney function
- Culture and sensitivity reports were available
- Local hospital antibiotic stewardship guidelines
For paediatric patients, dosing is weight-based — typically 20 to 80 mg/kg once daily for children aged 15 days to 12 years. For neonates up to 14 days, the maximum dose is 50 mg/kg per day.
Always reconstitute with the supplied sterile water for injection immediately before use. Do not mix with other antibiotics in the same infusion unless specifically instructed.
Note for Prescribers: Use with caution in patients with known penicillin allergy due to cross-sensitivity risk. Monitor renal function in patients with pre-existing kidney disease. Do not use in neonates with hyperbilirubinemia.
About Cubic Lifesciences: Why Trust This Manufacturer?
Cubic Lifesciences Private Limited was established in 2013 and has grown into one of India’s respected ethical pharmaceutical companies, headquartered in Panchkula, Haryana, with a showroom at Midtown Business Park, Peer Muchalla, Panchkula.
- WHO-GMP and ISO 9001 Certified manufacturing facility
- Portfolio of 700+ pharmaceutical formulations across all major therapeutic categories
- 2,000+ active franchise and distribution partners across India
- Toll-free support: 1800202560 for franchise and product queries
- Ethical pharma marketing with full regulatory compliance
The CeftoQub range — including CeftoQub S-750 — is part of Cubic Lifesciences’ critical care injectable portfolio, which is manufactured under rigorous quality control at their HSIIDC Panchkula facility.
CeftoQub S-750 as a PCD Pharma Franchise Opportunity
For pharma franchise partners and distributors, the Ceftriaxone + Sulbactam injectable segment is one of the most commercially stable categories in the Indian pharmaceutical market. Here is why CeftoQub S-750 is a strong addition to your franchise portfolio:
High and Consistent Hospital Demand: Ceftriaxone-Sulbactam combinations are a staple in ICUs, surgical wards, and gynaecology departments across India — ensuring repeat, high-volume orders from hospitals and nursing homes.
Resistance-Era Relevance: As antibiotic resistance continues to rise in India, the demand for combination injectables like CeftoQub S-750 is only increasing — making this a future-proof product for your business.
Monopoly-Based Franchise Rights: Cubic Lifesciences offers exclusive territory rights to its franchise partners, protecting your market and giving you a strong competitive advantage in your district or region.
Full Marketing Support: Franchise partners receive high-quality visual aids, product cards, clinical literature, and marketing support to build confidence with hospital doctors and specialists.
Trusted Brand: Cubic Lifesciences has an established and growing reputation in the critical care segment, backed by WHO-GMP certified manufacturing and a 700+ product range.
Frequently Asked Questions
1. What is Ceftriaxone + Sulbactam injection used for?
Ceftriaxone + Sulbactam injection is used to treat serious bacterial infections that are resistant to standard antibiotics. Common uses include hospital-acquired pneumonia, septicemia (blood poisoning), intra-abdominal infections, pelvic inflammatory disease (PID), bone and joint infections (osteomyelitis), bacterial meningitis, complicated UTIs, and surgical prophylaxis. In India, it is also used in complicated Typhoid cases that have not responded to oral therapy.
2. Why is Sulbactam added to Ceftriaxone? What does it do?
Sulbactam is a beta-lactamase inhibitor. Many resistant bacteria produce enzymes called beta-lactamases that break down antibiotics like Ceftriaxone before they can work. Sulbactam deactivates these enzymes, allowing Ceftriaxone to work effectively even against resistant strains. Without Sulbactam, Ceftriaxone alone may fail in infections caused by ESBL-producing or other resistant bacteria, which are increasingly common in Indian hospitals.
3. What is the difference between CeftoQub and CeftoQub S-750?
CeftoQub contains only Ceftriaxone and is used for infections that are sensitive to standard cephalosporins. CeftoQub S-750 contains Ceftriaxone 500 mg plus Sulbactam 250 mg — the S stands for Sulbactam. CeftoQub S-750 is prescribed when the infection is suspected or confirmed to involve resistant bacteria, or when the clinical severity warrants a more powerful combination. Your doctor will determine which formulation is appropriate based on the infection and culture reports.
4. How quickly does Ceftriaxone + Sulbactam injection start working?
Because CeftoQub S-750 is given as an injection — either intravenously or intramuscularly — it reaches therapeutic levels in the bloodstream almost immediately. Most patients show a significant reduction in fever and clinical symptoms within 24 to 48 hours of starting treatment. However, it is essential to complete the full course of injections as prescribed by the doctor, even if the patient feels better earlier. Stopping early can allow resistant bacteria to survive.
5. Can patients with penicillin allergy use CeftoQub S-750?
Patients with a documented penicillin allergy should inform their doctor before receiving CeftoQub S-750. There is a known cross-sensitivity between penicillins and cephalosporins — meaning some people who are allergic to penicillin may also react to Ceftriaxone. The risk is generally low but real. The decision to use CeftoQub S-750 in a penicillin-allergic patient should be made carefully by the treating physician based on the severity of the infection and the allergy history.
6. What are the common side effects of Ceftriaxone + Sulbactam injection?
The most common side effects are mild and temporary. These include pain, swelling, or redness at the injection site (more common with IM administration), mild diarrhoea, skin rash, nausea, and headache. Rarely, more serious reactions such as severe allergic reactions (anaphylaxis), haemolytic anaemia, or elevated liver enzymes may occur. If any unusual or severe symptoms develop after the injection, the doctor should be informed immediately. This medicine must only be administered in a clinical setting where such reactions can be managed.
7. Is CeftoQub S-750 available for PCD Pharma Franchise in India?
Yes. CeftoQub S-750 is available for PCD Pharma Franchise through Cubic Lifesciences Private Limited. The company offers monopoly-based franchise rights to qualified partners across India. Franchise partners receive the product along with visual aids, promotional materials, and marketing support. The injectable critical care segment — including Ceftriaxone + Sulbactam combinations — is one of the highest-demand and most commercially stable segments in the Indian hospital pharma market.
CeftoQub S-750 — The Right Antibiotic for Resistant Infections
The rise of antibiotic resistance in India is not a future threat — it is a present reality being faced in hospitals and ICUs every day. In this environment, combination injectables like CeftoQub S-750 are not optional additions to the hospital formulary — they are clinical necessities.
CeftoQub S-750 by Cubic Lifesciences brings together the proven bactericidal power of Ceftriaxone and the resistance-breaking action of Sulbactam in a single, WHO-GMP certified, sterile injection — giving clinicians a reliable, fast-acting weapon against some of the most challenging infections encountered in Indian healthcare settings today.
For healthcare professionals, CeftoQub S-750 is a trusted tool for severe, resistant bacterial infections. For PCD Pharma Franchise partners, it is a commercially strong product with consistent hospital demand and full support from Cubic Lifesciences.
